Acorda Therapeutics Inc (ACORQ) Gross Profit Margin starting from the first quarter 2024 to first quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Acorda Therapeutics Inc   (ACORQ)


Acorda Therapeutics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACORQ Gross Profit Margin (Mar 31 2024)
Q1 		(Dec 31 2023)
Q4 		(Sep 30 2023)
Q3 		(Jun 30 2023)
Q2 		(Mar 31 2023)
Q1
Y / Y Revenue Change -8.85 %
Seq. Revenue Change -46.59 %
Revenue In Millions $20.29
Gross Profit Margin 81.73 %
Gross Profit Margin Total Ranking # 648
Gross Profit In Millions $16.58
Y / Y Gross Profit Change -12.84 %
Seq. Gross Profit Change -


Commenting First Quarter 2024 Gross Profit Margin
Acorda Therapeutics Inc achieved Gross Profit of $17 millions compare to Gross Loss of $0.00 millions booked in the previous quarter. Despite the sequential Revenue deterioration in Q1 of -46.59 % Acorda Therapeutics Inc managed to reduce Cost of Sales and turn into profitability by achieving a Gross Profit of 17 compare to Gross Loss of $0.00 millions realized in the previous quarter. Company accomplished Gross Profit Margin of 81.73 %, above company average.


Observing first quarter 2024 results within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 648.
Learn about Gross Margin
ACORQ's Gross Profit Margin first quarter 2024 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 104
Overall # 639

Gross Profit Margin Statistics
High Average Low
89.67 % 78.89 % 57.71 %
(Jun 30 2023)   (Sep 30 2021)


ACORQ Gross Income Trends • More of ACORQ's Profitabilty Ratios • ACORQ Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ACORQ's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ACORQ's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ACORQ's Competitors
Gross Profit Margin Profit Margin for Acorda Therapeutics Inc 's Suppliers
Gross Profit Margin Profit Margin for ACORQ's Customers

You may also want to know
ACORQ's Annual Growth Rates ACORQ's Profitability Ratios ACORQ's Asset Turnover Ratio ACORQ's Dividend Growth
ACORQ's Roe ACORQ's Valuation Ratios ACORQ's Financial Strength Ratios ACORQ's Gross Profit Growth
ACORQ's Roa ACORQ's Inventory Turnover Ratio ACORQ's Growth Rates ACORQ's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2024, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginMar 31 2024 MRQ Gross ProfitMar 31 2024 MRQ Revenue
Vir Biotechnology Inc   99.90 %$ 56.317  Millions$ 56.376  Millions
Immunocore Holdings Plc  99.65 %$ 70.256  Millions$ 70.502  Millions
Agenus Inc  99.62 %$ 27.898  Millions$ 28.005  Millions
Biocryst Pharmaceuticals Inc   98.64 %$ 91.496  Millions$ 92.761  Millions
Neurocrine Biosciences Inc   98.54 %$ 507.800  Millions$ 515.300  Millions
Exelixis Inc   95.00 %$ 403.970  Millions$ 425.226  Millions
Cyclo Therapeutics Inc   94.16 %$ 0.191  Millions$ 0.202  Millions
Tarsus Pharmaceuticals Inc   94.01 %$ 25.960  Millions$ 27.614  Millions
Lineage Cell Therapeutics Inc   93.21 %$ 1.346  Millions$ 1.444  Millions
Halozyme Therapeutics Inc   85.54 %$ 167.550  Millions$ 195.879  Millions
Acorda Therapeutics Inc   81.73 %$ 16.582  Millions$ 20.289  Millions
Aim Immunotech Inc   80.00 %$ 0.032  Millions$ 0.040  Millions
Gilead Sciences Inc   76.79 %$ 5,134.000  Millions$ 6,686.000  Millions
Biogen Inc   76.33 %$ 1,748.300  Millions$ 2,290.500  Millions
Zeo Scientifix Inc   74.89 %$ 0.847  Millions$ 1.131  Millions
Regenxbio Inc   72.58 %$ 11.339  Millions$ 15.622  Millions
Vericel Corporation  68.94 %$ 35.354  Millions$ 51.281  Millions
Bio techne Corp  67.43 %$ 204.599  Millions$ 303.428  Millions
Scilex Holding Company  64.72 %$ 7.044  Millions$ 10.884  Millions
Xtant Medical Holdings Inc   63.37 %$ 17.302  Millions$ 27.302  Millions
Amgen Inc   57.03 %$ 4,247.000  Millions$ 7,447.000  Millions
Dyadic International Inc   56.98 %$ 0.191  Millions$ 0.335  Millions
Adaptive Biotechnologies Corporation  56.89 %$ 23.822  Millions$ 41.873  Millions
Coherus Oncology inc   55.12 %$ 42.477  Millions$ 77.063  Millions
Repligen Corp  50.13 %$ 76.791  Millions$ 153.182  Millions
Elutia Inc   48.66 %$ 2.843  Millions$ 5.843  Millions
Champions Oncology Inc   48.22 %$ 6.752  Millions$ 14.002  Millions
Adma Biologics Inc   48.22 %$ 39.108  Millions$ 81.108  Millions
Enzo Biochem Inc  46.53 %$ 3.733  Millions$ 8.022  Millions
Moderna Inc   42.51 %$ 71.000  Millions$ 167.000  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.